Austin Winder, contributing author for LOC Scientific, looks at how automation could benefit drug research and development.
Lab automation
When it comes to developing prescription drugs, automation tools are no longer a luxury; rather they represent the future of pharmaceutical development. Lab work that is done by robots in a sterile area leads to an environment free of contamination, which makes the data gathered more valuable than ever before, and this will lead to useful drugs being developed more quickly and in greater numbers. Medicine as a whole will benefit as a result.
Cancer and genomic research
In particular, automation will be critical in cancer research. The population is growing and ageing, and there is increasing demand for breakthroughs in cancer-treating drugs. When it comes to precision medicine, automation will help bring down the costs of cancer drugs that are more personalised. Genomic research is also benefiting from automation because of the field's emphasis on gathering massive amounts of data, and automation will lead to better results and more sound conclusions.Automation will lead to greater efficiency in the lab, and this is speeding up every aspect of drug development. As a result, pharmaceutical companies will be able to get their new drugs through the FDA approval phase faster. As technicians are replaced by automation, costs will get even lower. This trend has already begun, and the total amount of money invested in automation is estimated to be at 1.3 billion dollars by the beginning of 2028.